|View printer-friendly version|
|July 05, 2004 5:10 p.m.|
|Teva Receives Approvable Letter For Agilect® (Rasagiline)|
Jerusalem, Israel, July 5, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for once-daily AGILECT® (rasagiline mesylate) as a treatment for Parkinson's disease (PD) as initial monotherapy in early PD patients and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease. Following the approvable letter, Teva will work together with the FDA to complete the process of receiving final approval as soon as possible.